SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
SIGA Technologies (NASDAQ: SIGA), a commercial-stage pharmaceutical company, has scheduled a business update conference call and webcast for August 5, 2025, at 4:30 PM ET. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire discussing the company's second-quarter 2025 results.
Investors can access the call through a domestic dial-in (1-800-717-1738) or international dial-in (1-646-307-1865). A replay will be available for two weeks, and the webcast will be accessible through SIGA's investor relations website.
SIGA Technologies (NASDAQ: SIGA), un'azienda farmaceutica in fase commerciale, ha programmato una conferenza telefonica e webcast per l'aggiornamento aziendale il 5 agosto 2025 alle 16:30 ET. Alla chiamata parteciperanno l'amministratore delegato Diem Nguyen e il direttore finanziario Daniel Luckshire, che discuteranno i risultati del secondo trimestre 2025 della società.
Gli investitori potranno accedere alla chiamata tramite il numero nazionale (1-800-717-1738) o il numero internazionale (1-646-307-1865). La registrazione sarà disponibile per due settimane, e il webcast sarà accessibile attraverso il sito web delle relazioni con gli investitori di SIGA.
SIGA Technologies (NASDAQ: SIGA), una empresa farmacéutica en etapa comercial, ha programado una conferencia telefónica y webcast para la actualización empresarial el 5 de agosto de 2025 a las 4:30 PM ET. La llamada contará con la participación del CEO Diem Nguyen y el CFO Daniel Luckshire, quienes discutirán los resultados del segundo trimestre de 2025 de la compañía.
Los inversores pueden acceder a la llamada a través de una línea nacional (1-800-717-1738) o internacional (1-646-307-1865). La repetición estará disponible durante dos semanas y el webcast será accesible a través del sitio web de relaciones con inversores de SIGA.
SIGA Technologies (NASDAQ: SIGA)는 상업 단계에 있는 제약회사로서 2025년 8월 5일 오후 4시 30분(동부시간)에 사업 업데이트 컨퍼런스 콜과 웹캐스트를 예정하고 있습니다. 이번 콜에는 CEO Diem Nguyen과 CFO Daniel Luckshire가 참석하여 회사의 2025년 2분기 실적에 대해 논의할 예정입니다.
투자자들은 국내 전화번호(1-800-717-1738) 또는 국제 전화번호(1-646-307-1865)를 통해 콜에 참여할 수 있습니다. 재청취는 2주간 가능하며, 웹캐스트는 SIGA 투자자 관계 웹사이트에서 접속할 수 있습니다.
SIGA Technologies (NASDAQ: SIGA), une entreprise pharmaceutique en phase commerciale, a programmé une conférence téléphonique et un webcast pour une mise à jour commerciale le 5 août 2025 à 16h30 ET. La conférence inclura le PDG Diem Nguyen et le directeur financier Daniel Luckshire, qui discuteront des résultats du deuxième trimestre 2025 de la société.
Les investisseurs peuvent accéder à l'appel via un numéro national (1-800-717-1738) ou international (1-646-307-1865). La rediffusion sera disponible pendant deux semaines et le webcast accessible via le site web des relations investisseurs de SIGA.
SIGA Technologies (NASDAQ: SIGA), ein Pharmaunternehmen in der kommerziellen Phase, hat eine Telefonkonferenz und einen Webcast zur Geschäftsaktualisierung für den 5. August 2025 um 16:30 Uhr ET angesetzt. An dem Anruf werden CEO Diem Nguyen und CFO Daniel Luckshire teilnehmen, um die Ergebnisse des zweiten Quartals 2025 des Unternehmens zu besprechen.
Investoren können über eine nationale Einwahlnummer (1-800-717-1738) oder eine internationale Einwahlnummer (1-646-307-1865) teilnehmen. Eine Aufzeichnung wird zwei Wochen lang verfügbar sein, und der Webcast kann über die Investor-Relations-Website von SIGA abgerufen werden.
- None.
- None.
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.
A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time.
Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers.
A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130215. The archived webcast will be available in the Investor Relations section of the Company's website.
About SIGA
SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit www.siga.com.
Contacts:
Suzanne Harnett
sharnett@siga.com
and
| Investors | Media |
| Jennifer Drew-Bear, Edison Group Jdrew-bear@edisongroup.com | Holly Stevens, CG Life hstevens@cglife.com |
FAQ
When is SIGA's Q2 2025 earnings call scheduled for?
How can investors access SIGA's Q2 2025 earnings call?
Who will be presenting at SIGA's Q2 2025 earnings call?
How long will SIGA's Q2 2025 earnings call replay be available?
